Corporation
Novartis Pharmaceuticals Canada Inc.
- Meetings this Parliament
- 36
- With MPs
- 15
- Since Nov 2021
- 93
- Active registrations
- 1
Most recent reported meeting: Sep 23, 2026.
Lobbying by Novartis Pharmaceuticals Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since May 19, 2026
Filed by Dimitri Gitas, Country President
Lobbyists
- Guillaume Demers · Director - Public Affairs
-
Shona Kinley · Vice-President Public Affairs
Former public office holder
Formerly Special Assistant, Minister's Office, Health Canada (1996–1996)
Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canadian Heritage (PCH), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Natural Resources Canada (NRCan), Pacific Economic Development Canada (PacifiCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (9)Hide details
- The CUSMA renegotiation and issues related to the pharmaceutical industry in Canada.
- Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.
- Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA"
- Patented Medicines Regulations modernization as outlined in Budget 2026, that will leverage existing technology, enabling faster and more cost effective procedural processes.
- Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
- R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
- Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
- Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
- Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
Registration 962869-15599-43. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Mark Vineis (35), Dimitri Gitas (21), Andrea Marazzi (17), Christian Macher (14), Pedro Ferreira (6).
-
Reported by Mark Vineis · In-house (corporation)
- Pam Damoff · Member of Parliament, House of Commons
- Benjamin Wiles · Special Assistant to MP Damoff, House of Commons
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
- Benoit Leduc · Manager, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Tom Kmiec · Member of Parliament, Calgary Shephard
- Julie Fielder · Special Assistant to MP Kmiec, House of Commons
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Francesco Sorbara · Member of Parliment, House of Commons
HealthIndustryResearch and Development
-
Reported by Mark Vineis · In-house (corporation)
- Rachel Blaney · Member of Parliament North Island Powell River, House of Commons
HealthResearch and Development
-
Reported by Mark Vineis · In-house (corporation)
- Tom Kmiec · Member of Parliament, Calgary Shephard
HealthIndustryScience and Technology
-
Reported by Pedro Ferreira · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustryScience and Technology
-
Reported by Pedro Ferreira · In-house (corporation)
- Simon Kennedy · Sous-ministre, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustryScience and Technology
-
Reported by Pedro Ferreira · In-house (corporation)
- Gurjiven Sandhu · Director of Policy, Pacific Economic Development Canada (PacifiCan)
- Jessica La Forge · Policy Advisor, Pacific Economic Development Canada (PacifiCan)
HealthScience and Technology
-
Reported by Pedro Ferreira · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Health
-
Reported by Pedro Ferreira · In-house (corporation)
- Chandra Arya · Member of Parliament, House of Commons
Health
-
Reported by Pedro Ferreira · In-house (corporation)
- Francesco Sorbara · Member of Parliment, House of Commons
HealthIndustry
-
Reported by Andrea Marazzi · In-house (corporation)
- Simon Kennedy · Sous-ministre, Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
- Christopher Johnstone · Assistant Deputy minister, Health Canada (HC)
HealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Mark Holland · Minister of Health, Health Canada (HC)
HealthScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Jocelyne Voisin · Assistant Deputy Minister, Health Canada (HC)
HealthResearch and DevelopmentScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Jean-Yves Duclos · Minister of Health, Health Canada (HC)
- Jean-Sébastien Bock · Director of Policy, Health Canada (HC)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
HealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Andy Fillmore · Member of Parliament, House of Commons
HealthIndustryScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Bianca Hossain · Policy advisor, Innovation, Science and Economic Development Canada (ISED)
HealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Jocelyne Voisin · Assistant Deputy Minister, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
HealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Andy Fillmore · Member of Parliament, House of Commons
HealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Pierre-Yves Bourque · Director of Operations, Innovation, Science and Economic Development Canada (ISED)
- Jaxson Khan · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Bianca Hossain · Policy advisor, Innovation, Science and Economic Development Canada (ISED)
HealthScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Chris Zou · Policy Advisor, Global Affairs Canada (GAC)
HealthScience and Technology
-
Reported by Andrea Marazzi · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
HealthResearch and Development
-
Reported by Andrea Marazzi · In-house (corporation)
- Jessie Pierre · Director of Policy, Federal Economic Development Agency for Southern Ontario (FedDev)
- Ashley Wright · Chief of Staff to the Minister, Pacific Economic Development Canada (PacifiCan)
- Zachary Nixon · Chief of Staff to the Minister, Global Affairs Canada (GAC)
- Chris Zou · Policy Advisor, Global Affairs Canada (GAC)
and 2 moreShow fewer
- Alexandre Boulé · Director Regional Affairs, Canadian Heritage (PCH)
- Camille Benoit-Blouin · Special Assistant, Policy, Global Affairs Canada (GAC)
HealthIndustryResearch and DevelopmentScience and Technology
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.